IP Library › Granted Patent US 12,697,301
Granted Patent B2
US 12,697,301 · App. 17/389,016 · Granted Aug 4, 2026

Pulmonary delivery of mRNA to non-lung target cells

Inventors: Michael Heartlein (Lexington, MA); Braydon Charles Guild (Lexington, MA); Frank DeRosa (Lexington, MA); Carsten Rudolph (Martinsried, DE); Christian Plank (Martinsried, DE)
Assignee: TRANSLATE BIO, INC.
A61K9/0073A61K31/7088A61M15/009A61M16/14C12N15/88A61K48/0075
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,697,301
App. No.
17/389,016
Granted
Aug 4, 2026
Kind
B2
Abstract

Compositions comprising mRNA formulated for pulmonary administration and related methods for delivery of the mRNA and/or encoded protein to a non-lung cell or tissue. The compositions and methods may be used to prevent or ameliorate the symptoms of diseases associated with the mRNA encoded protein.

Claims (23)

1 . A composition comprising one or more mRNA encoding an antibody and a lipid carrier vehicle, wherein the composition is formulated for pulmonary delivery, wherein the antibody is a full-length antibody, Fab, Fv, or single-chain Fv, wherein the lipid carrier vehicle comprises one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more PEG-modified lipids, wherein the cationic lipid comprises a molar ratio of about 20% to about 70% of the total lipid present in the lipid carrier vehicle, wherein the composition is contained in a device suitable for delivery to the lungs.

2 . The composition of claim 1 , wherein the one or more cationic lipids are selected from the group consisting of C12-200, HGT4003, HGT5000, HGT5001, ICE, DLinKC2-DMA, DODAP, DODMA, DLinDMA, CLinDMA, and combinations thereof.

3 . The composition of claim 1 , wherein the one or more non-cationic lipids are selected from the group consisting of distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolamine (POPE), dioleoyl-phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoyl-phosphatidyl-ethanolamine (DSPE), 16-O-monomethyl PE, 16-O-dimethyl PE, 18-1-trans PE, 1-stearoyl-2-oleoyl-phosphatidylethanolamine (SOPE), cholesterol, or a mixture thereof.

4 . The composition of claim 1 , wherein the one or more PEG-modified lipids comprise a polyethylene glycol chain of up to 5 kDa in molecular weight covalently attached to a lipid with alkyl chain(s) of C 6 -C 20 length.

5 . The composition according to claim 1 , wherein the lipid carrier vehicle is a liposome or lipid nanoparticle.

6 . The composition according to claim 1 , wherein the one or more mRNAs are encapsulated in the same lipid carrier vehicle.

7 . The composition according to claim 1 , wherein the antibody is comprised of a heavy chain and a light chain, and wherein the heavy chain and the light chain are encoded by a single mRNA.

8 . The composition according to claim 1 , wherein the antibody is comprised of a heavy chain and a light chain, and wherein the heavy chain and the light chain are encoded by separate mRNAs.

9 . The composition according to claim 7 , wherein the heavy chain and the light chain of the antibody are present at varying ratios.

10 . The composition according to claim 1 , wherein the antibody is detectable in a non-lung cell or tissue of a subject for at least 6 hours following administration of the composition to a lung of the subject.

11 . The composition according to claim 1 , wherein the antibody is detectable in a non-lung cell or tissue of a subject for at least 1 day following administration of the composition to a lung of the subject.

12 . The composition according to claim 10 , wherein the non-lung cell is selected from the group consisting of hepatocytes, epithelial cells, hematopoietic cells, epithelial cells, endothelial cells, bone cells, stem cells, mesenchymal cells, neural cells, cardiac cells, adipocytes, vascular smooth muscle cells, cardiomyocytes, skeletal muscle cells, beta cells, pituitary cells, synovial lining cells, ovarian cells, testicular cells, fibroblasts, B cells, T cells, reticulocytes, leukocytes, granulocytes, macrophages, neutrophils, antigen presenting cells (dendritic cells), fibroblasts, tumor cells and combinations thereof.

13 . The composition according to claim 10 , wherein the non-lung tissue is selected from the group consisting of heart, liver, spleen, kidneys, skeletal muscle, lymph nodes, skin, brain, cerebrospinal fluid, plasma and combinations thereof.

14 . The composition according to claim 1 , wherein the composition is formulated as respirable particles.

15 . The composition according to claim 14 , wherein the respirable particles have a size less than about 500 μm.

16 . The composition according to claim 1 , wherein the composition is formulated as a nebulizable liquid.

17 . The composition according to claim 1 , wherein the composition is formulated as a dry powder.

18 . The composition of claim 1 , wherein the one or more non-cationic lipids is DOPE, the one or more cholesterol-based lipids is Cholesterol, and the one or more PEG-modified lipids is DMG-PEG2000 or DMG-PEG2K.

19 . A composition comprising one or more mRNA encoding an antibody and a lipid carrier vehicle, wherein the composition is formulated for pulmonary delivery, wherein the antibody is a full-length antibody, Fab, Fv, or single-chain Fv, wherein the lipid carrier vehicle comprises one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more PEG-modified lipids, wherein the non-cationic lipid comprises a molar ratio of about 10% to about 70% of the total lipid present in the lipid carrier vehicle.

20 . The composition of claim 1 , wherein the cationic lipid, the non-cationic lipid, Cholesterol, and the PEG-modified lipid are in a molar ratio of 40:30:25:5, 18:56:20:6, or 40:20:35:5, respectively.

21 . The composition of claim 1 , wherein the cationic lipid, DOPE, Cholesterol, and DMG-PEG2000 are in a molar ratio of 40:30:25:5, 18:56:20:6, or 40:20:35:5, respectively.

22 . The composition of claim 1 , wherein the cationic lipid, DSPC, Cholesterol, and DMG-PEG2000 are in a molar ratio of 40:30:25:5, 18:56:20:6, or 40:20:35:5, respectively.

23 . The composition of claim 1 , wherein the device is a metered dose inhaler, a jet-nebulizer, a ultrasonic nebulizer, a dry-powder-inhaler, a propellant-based inhaler, or an insufflator.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2022
From: RUDOLPH, CARSTEN; PLANK, CHRISTIAN
To: ETHRIS GMBH
Reel/Frame 060620/0595 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2022
From: HEARTLEIN, MICHAEL; GUILD, BRAYDON CHARLES; DEROSA, FRANK
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 060620/0813 →
CHANGE OF NAME Recorded Jul 26, 2022
From: RANA THERAPEUTICS, INC.
To: TRANSLATE BIO, INC.
Reel/Frame 060919/0044 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2022
From: SHIRE HUMAN GENETIC THERAPIES, INC.
To: RANA THERAPEUTICS, INC.
Reel/Frame 061039/0895 →
Continuity (4)
Division 16258191 · Jan 25, 2019
Division 14406504 · Jun 7, 2013
Provisional Application 61657452 · Jun 8, 2012
Related Publication 20220226236A1 · Jul 21, 2022
References Cited (289)
US 5705385A · Bally et al. · 1998 [cited by applicant]
US 5965434A · Wolff et al. · 1999 [cited by applicant]
US 5976567A · Wheeler · 1999 [cited by applicant]
US 5981501A · Wheeler et al. · 1999 [cited by applicant]
US 6077835A · Hanson et al. · 2000 [cited by applicant]
US 6534484B1 · Wheeler et al. · 2003 [cited by applicant]
US 6734171B1 · Saravolac et al. · 2004 [cited by applicant]
US 6815432B2 · Wheeler et al. · 2004 [cited by applicant]
US 7422902B1 · Wheeler et al. · 2008 [cited by applicant]
US 7745651B2 · Heyes et al. · 2010 [cited by applicant]
US 7799565B2 · MacLachlan et al. · 2010 [cited by applicant]
US 7803397B2 · Heyes et al. · 2010 [cited by applicant]
US 7901708B2 · MacLachlan et al. · 2011 [cited by applicant]
US 8101741B2 · MacLachlan et al. · 2012 [cited by applicant]
US 8188263B2 · MacLachlan et al. · 2012 [cited by applicant]
US 8236943B2 · Lee et al. · 2012 [cited by applicant]
US 8329070B2 · MacLachlan et al. · 2012 [cited by applicant]
US 8513403B2 · MacLachlan et al. · 2013 [cited by applicant]
US 8569256B2 · Heyes et al. · 2013 [cited by applicant]
US 8710200B2 · Schrum et al. · 2014 [cited by applicant]
US 8822663B2 · Schrum et al. · 2014 [cited by applicant]
US 8853377B2 · Guild et al. · 2014 [cited by applicant]
US 8883202B2 · Manoharan et al. · 2014 [cited by applicant]
US 8936942B2 · Heyes et al. · 2015 [cited by applicant]
US 8969353B2 · Mahon et al. · 2015 [cited by applicant]
US 8980864B2 · Hoge et al. · 2015 [cited by applicant]
US 8999351B2 · Manoharan et al. · 2015 [cited by applicant]
US 8999950B2 · MacLachlan et al. · 2015 [cited by applicant]
US 9018187B2 · Heyes et al. · 2015 [cited by applicant]
US 9051567B2 · Fitzgerald et al. · 2015 [cited by applicant]
US 9061059B2 · Chakraborty et al. · 2015 [cited by applicant]
US 9074208B2 · MacLachlan et al. · 2015 [cited by applicant]
US 9089604B2 · Chakraborty et al. · 2015 [cited by applicant]
US 9095552B2 · Chakraborty et al. · 2015 [cited by applicant]
US 9107886B2 · Chakraborty et al. · 2015 [cited by applicant]
US 9114113B2 · Chakraborty et al. · 2015 [cited by applicant]
US 9181319B2 · Schrum et al. · 2015 [cited by applicant]
US 9186325B2 · Manoharan et al. · 2015 [cited by applicant]
US 9186372B2 · de Fougerolles et al. · 2015 [cited by applicant]
US 9187748B2 · Geisbert et al. · 2015 [cited by applicant]
US 9192651B2 · Chakraborty et al. · 2015 [cited by applicant]
US 9220682B2 · Manoharan et al. · 2015 [cited by applicant]
US 9220755B2 · Chakraborty et al. · 2015 [cited by applicant]
US 9220792B2 · Chakraborty et al. · 2015 [cited by applicant]
US 9233141B2 · Chakraborty et al. · 2016 [cited by applicant]
US 9254311B2 · Bancel et al. · 2016 [cited by applicant]
US 9295689B2 · de Fougerolles et al. · 2016 [cited by applicant]
US 9301993B2 · Chakraborty et al. · 2016 [cited by applicant]
US 9303079B2 · Chakraborty et al. · 2016 [cited by applicant]
US 9334328B2 · Schrum et al. · 2016 [cited by applicant]
US 9345780B2 · Manoharan et al. · 2016 [cited by applicant]
US 9352042B2 · Heyes et al. · 2016 [cited by applicant]
US 9352048B2 · Manoharan et al. · 2016 [cited by applicant]
US 9364435B2 · Yaworski et al. · 2016 [cited by applicant]
US 9394234B2 · Chen et al. · 2016 [cited by applicant]
US 9404127B2 · Yaworski et al. · 2016 [cited by applicant]
US 9428751B2 · MacDonald et al. · 2016 [cited by applicant]
US 9464124B2 · Bancel et al. · 2016 [cited by applicant]
US 9492386B2 · MacLachlan et al. · 2016 [cited by applicant]
US 9504651B2 · MacLachlan et al. · 2016 [cited by applicant]
US 9504734B2 · Bancel et al. · 2016 [cited by applicant]
US 9518272B2 · Yaworksi et al. · 2016 [cited by applicant]
US 9546128B2 · DeRosa et al. · 2017 [cited by applicant]
US 9572874B2 · Fotin-Mleczek et al. · 2017 [cited by applicant]
US 9572896B2 · Bancel et al. · 2017 [cited by applicant]
US 9572897B2 · Bancel et al. · 2017 [cited by applicant]
US 9587003B2 · Bancel et al. · 2017 [cited by applicant]
US 20020192651A1 · Wheeler et al. · 2002 [cited by applicant]
US 20030181410A1 · Wheeler et al. · 2003 [cited by applicant]
US 20040142025A1 · MacLachlan et al. · 2004 [cited by applicant]
US 20040224912A1 · Dobie et al. · 2004 [cited by applicant]
US 20050158302A1 · Faustman et al. · 2005 [cited by applicant]
US 20060008910A1 · MacLachlan et al. · 2006 [cited by applicant]
US 20060083780A1 · Heyes et al. · 2006 [cited by applicant]
US 20070135372A1 · MacLachlan et al. · 2007 [cited by applicant]
US 20090270481A1 · MacLachlan et al. · 2009 [cited by applicant]
US 20090286582A1 · Kormann et al. · 2009 [cited by applicant]
US 20090286852A1 · Kariko et al. · 2009 [cited by applicant]
US 20100041152A1 · Wheeler et al. · 2010 [cited by applicant]
US 20110244026A1 · Guild et al. · 2011 [cited by applicant]
US 20110256175A1 · Hope et al. · 2011 [cited by applicant]
US 20110311583A1 · Manoharan et al. · 2011 [cited by applicant]
US 20120065252A1 · Schrum et al. · 2012 [cited by applicant]
US 20120128760A1 · Manoharan et al. · 2012 [cited by applicant]
US 20120142756A1 · Guild et al. · 2012 [cited by applicant]
US 20120202871A1 · Heyes et al. · 2012 [cited by applicant]
US 20120237975A1 · Schrum et al. · 2012 [cited by applicant]
US 20120251618A1 · Schrum et al. · 2012 [cited by applicant]
US 20120328668A1 · MacLachlan et al. · 2012 [cited by applicant]
US 20130177640A1 · Geall et al. · 2013 [cited by applicant]
US 20130195967A1 · Guild et al. · 2013 [cited by applicant]
US 20130237594A1 · de Fougerolles et al. · 2013 [cited by applicant]
US 20130259923A1 · Bancel et al. · 2013 [cited by applicant]
US 20130259924A1 · Bancel et al. · 2013 [cited by applicant]
US 20130266640A1 · de Fougerolles et al. · 2013 [cited by applicant]
US 20140010861A1 · Bancel et al. · 2014 [cited by applicant]
US 20140044772A1 · MacLachlan et al. · 2014 [cited by applicant]
US 20140105964A1 · Bancel et al. · 2014 [cited by applicant]
US 20140105965A1 · Bancel et al. · 2014 [cited by applicant]
US 20140147432A1 · Bancel et al. · 2014 [cited by applicant]
US 20140147454A1 · Chakraborty et al. · 2014 [cited by applicant]
US 20140148502A1 · Bancel et al. · 2014 [cited by applicant]
US 20140155472A1 · Bancel et al. · 2014 [cited by applicant]
US 20140155473A1 · Bancel et al. · 2014 [cited by applicant]
US 20140155474A1 · Bancel et al. · 2014 [cited by applicant]
US 20140155475A1 · Bancel et al. · 2014 [cited by applicant]
US 20140171485A1 · Bancel et al. · 2014 [cited by applicant]
US 20140179756A1 · MacLachlan et al. · 2014 [cited by applicant]
US 20140179771A1 · Bancel et al. · 2014 [cited by applicant]
US 20140186432A1 · Bancel et al. · 2014 [cited by applicant]
US 20140193482A1 · Bancel et al. · 2014 [cited by applicant]
US 20140194494A1 · Bancel et al. · 2014 [cited by applicant]
US 20140199371A1 · Bancel et al. · 2014 [cited by applicant]
US 20140200261A1 · Hoge et al. · 2014 [cited by applicant]
US 20140200262A1 · Bancel et al. · 2014 [cited by applicant]
US 20140200263A1 · Bancel et al. · 2014 [cited by applicant]
US 20140200264A1 · Bancel et al. · 2014 [cited by applicant]
US 20140206752A1 · Afeyan et al. · 2014 [cited by applicant]
US 20140206753A1 · Guild et al. · 2014 [cited by applicant]
US 20140206755A1 · Bancel et al. · 2014 [cited by applicant]
US 20140206852A1 · Hoge et al. · 2014 [cited by applicant]
US 20140221465A1 · Bancel et al. · 2014 [cited by applicant]
US 20140243399A1 · Schrum et al. · 2014 [cited by applicant]
US 20140249208A1 · Bancel et al. · 2014 [cited by applicant]
US 20140255467A1 · Bancel et al. · 2014 [cited by applicant]
US 20140255468A1 · Bancel et al. · 2014 [cited by applicant]
US 20140275227A1 · Hoge et al. · 2014 [cited by applicant]
US 20140275229A1 · Bancel et al. · 2014 [cited by applicant]
US 20140294937A1 · MacLachlan et al. · 2014 [cited by applicant]
US 20140343129A1 · de Fougerolles et al. · 2014 [cited by applicant]
US 20150005372A1 · Hoge et al. · 2015 [cited by applicant]
US 20150017211A1 · de Fougerolles et al. · 2015 [cited by applicant]
US 20150044277A1 · Bancel et al. · 2015 [cited by applicant]
US 20150050354A1 · Bouchon et al. · 2015 [cited by applicant]
US 20150051268A1 · Bancel et al. · 2015 [cited by applicant]
US 20150056253A1 · Bancel et al. · 2015 [cited by applicant]
US 20150064235A1 · Bancel et al. · 2015 [cited by applicant]
US 20150064236A1 · Bancel et al. · 2015 [cited by applicant]
US 20150064242A1 · Heyes et al. · 2015 [cited by applicant]
US 20150064725A1 · Schrum et al. · 2015 [cited by applicant]
US 20150086614A1 · Bancel et al. · 2015 [cited by applicant]
US 20150111248A1 · Bancel et al. · 2015 [cited by applicant]
US 20150111945A1 · Geisbert et al. · 2015 [cited by applicant]
US 20150166465A1 · Chen et al. · 2015 [cited by applicant]
US 20150190515A1 · Manoharan et al. · 2015 [cited by applicant]
US 20150265708A1 · Manoharan et al. · 2015 [cited by applicant]
US 20150315541A1 · Bancel et al. · 2015 [cited by applicant]
US 20150315584A1 · MacDonald et al. · 2015 [cited by applicant]
US 20150366997A1 · Guild et al. · 2015 [cited by applicant]
US 20160095924A1 · Hope et al. · 2016 [cited by applicant]
US 20160114011A1 · Bancel et al. · 2016 [cited by applicant]
US 20160115477A1 · MacLachlan et al. · 2016 [cited by applicant]
US 20160115483A1 · MacLachlan et al. · 2016 [cited by applicant]
US 20160136236A1 · Hoge et al. · 2016 [cited by applicant]
US 20160151284A1 · Heyes et al. · 2016 [cited by applicant]
US 20160158385A1 · Bancel et al. · 2016 [cited by applicant]
US 20160193299A1 · de Fougerolles et al. · 2016 [cited by applicant]
US 20160194368A1 · Hoge et al. · 2016 [cited by applicant]
US 20160194625A1 · Hoge et al. · 2016 [cited by applicant]
US 20160213785A1 · Manoharan et al. · 2016 [cited by applicant]
US 20160237108A1 · Fraley et al. · 2016 [cited by applicant]
US 20160237134A1 · Hoge et al. · 2016 [cited by applicant]
US 20160250354A1 · Manoharan et al. · 2016 [cited by applicant]
US 20160251681A1 · Yaworski et al. · 2016 [cited by applicant]
US 20160256567A1 · Heyes et al. · 2016 [cited by applicant]
US 20160256568A1 · Heyes et al. · 2016 [cited by applicant]
US 20160256573A1 · de Fougerolles et al. · 2016 [cited by applicant]
US 20160264971A1 · Geisbert et al. · 2016 [cited by applicant]
US 20160264975A1 · Schrum et al. · 2016 [cited by applicant]
US 20160274089A1 · Ciufolini et al. · 2016 [cited by applicant]
US 20160304552A1 · Roy et al. · 2016 [cited by applicant]
US 20160317647A1 · Ciaramella et al. · 2016 [cited by applicant]
US 20160317676A1 · Hope et al. · 2016 [cited by applicant]
US 20160331828A1 · Ciaramella et al. · 2016 [cited by applicant]
US 20160348099A1 · Roy et al. · 2016 [cited by applicant]
US 20160354490A1 · Roy et al. · 2016 [cited by applicant]
US 20160354491A1 · Roy et al. · 2016 [cited by applicant]
US 20160354492A1 · Roy et al. · 2016 [cited by applicant]
US 20160354493A1 · Roy et al. · 2016 [cited by applicant]
US 20160367687A1 · Manoharan et al. · 2016 [cited by applicant]
US 20160367702A1 · Hoge et al. · 2016 [cited by applicant]
US 20160375134A1 · Bancel et al. · 2016 [cited by applicant]
US 20160375137A9 · Manoharan et al. · 2016 [cited by applicant]
US 20170000858A1 · Fotin-Mleczek et al. · 2017 [cited by applicant]
US 20170000870A1 · Hoerr et al. · 2017 [cited by applicant]
US 20170000871A1 · Probst et al. · 2017 [cited by applicant]
US 20170002060A1 · Bolen et al. · 2017 [cited by applicant]
US 20170007702A1 · Heyes et al. · 2017 [cited by applicant]
US 20170014496A1 · Fotin-Mleczek et al. · 2017 [cited by applicant]
US 20170028059A1 · Baumhoff et al. · 2017 [cited by applicant]
US 20170029847A1 · Thess · 2017 [cited by applicant]
US 20170042814A1 · Yaworski et al. · 2017 [cited by applicant]
US 20170056529A1 · Thess et al. · 2017 [cited by applicant]
CA 2807552 · 2012 [cited by applicant]
EP 1519714 · 2010 [cited by applicant]
EP 2449106 · 2012 [cited by applicant]
EP 2338478 · 2013 [cited by applicant]
EP 2823809 · 2015 [cited by applicant]
WO WO1990011092 · 1990 [cited by applicant]
WO WO1993003709 · 1993 [cited by applicant]
WO WO1993012756 · 1993 [cited by applicant]
WO WO1998010748 · 1998 [cited by applicant]
WO WO2000059548 · 2000 [cited by applicant]
WO WO2004067026 · 2004 [cited by applicant]
WO WO2005026372 · 2005 [cited by applicant]
WO WO2005120152 · 2005 [cited by applicant]
WO WO2005121348 · 2005 [cited by applicant]
WO WO2006016097 · 2006 [cited by applicant]
WO WO2009127060 · 2006 [cited by applicant]
WO WO2007024708 · 2007 [cited by applicant]
WO WO2010042877 · 2010 [cited by applicant]
WO WO2010056403 · 2010 [cited by applicant]
WO WO2010110314 · 2010 [cited by applicant]
WO WO2011068810 · 2011 [cited by applicant]
WO WO2011071931 · 2011 [cited by applicant]
WO WO2011141705 · 2011 [cited by applicant]
WO WO2012019168 · 2012 [cited by applicant]
WO WO2012170930 · 2012 [cited by applicant]
WO WO2012135805 · 2012 [cited by applicant]
WO WO2013039857 · 2013 [cited by applicant]
WO WO2013039861 · 2013 [cited by applicant]
WO WO2013090186 · 2013 [cited by applicant]
WO WO2013101690 · 2013 [cited by applicant]
WO WO2013126803 · 2013 [cited by applicant]
WO WO2013130161 · 2013 [cited by applicant]
WO WO2013149140 · 2013 [cited by applicant]
WO WO2013151663 · 2013 [cited by applicant]
WO WO2013151664 · 2013 [cited by applicant]
WO WO2013151666 · 2013 [cited by applicant]
WO WO2013151667 · 2013 [cited by applicant]
WO WO2013151668 · 2013 [cited by applicant]
WO WO2013151670 · 2013 [cited by applicant]
WO WO2013151671 · 2013 [cited by applicant]
WO WO2013151672 · 2013 [cited by applicant]
WO WO2013151736 · 2013 [cited by applicant]
WO WO2014089486 · 2013 [cited by applicant]
WO WO2014113089 · 2014 [cited by applicant]
WO WO2014144039 · 2014 [cited by applicant]
WO WO2014144711 · 2014 [cited by applicant]
WO WO2014144767 · 2014 [cited by applicant]
WO WO2014152027 · 2014 [cited by applicant]
WO WO2014152030 · 2014 [cited by applicant]
WO WO2014152031 · 2014 [cited by applicant]
WO WO2014152211 · 2014 [cited by applicant]
WO WO2014152540 · 2014 [cited by applicant]
WO WO2014158795 · 2014 [cited by applicant]
WO WO2014159813 · 2014 [cited by applicant]
WO WO2015006747 · 2015 [cited by applicant]
WO WO2015048744 · 2015 [cited by applicant]
WO WO2015051169 · 2015 [cited by applicant]
WO WO2015051173 · 2015 [cited by applicant]
WO WO2015058069 · 2015 [cited by applicant]
WO WO2015085318 · 2015 [cited by applicant]
WO WO2015089511 · 2015 [cited by applicant]
WO WO2015011633 · 2016 [cited by applicant]
WO WO2016054421 · 2016 [cited by applicant]
WO WO2016071857 · 2016 [cited by applicant]
WO WO2016077123 · 2016 [cited by applicant]
WO WO2016077125 · 2016 [cited by applicant]
WO WO2016118724 · 2016 [cited by applicant]
WO WO2016118725 · 2016 [cited by applicant]
WO WO2016154127 · 2016 [cited by applicant]
WO WO2016164762 · 2016 [cited by applicant]
WO WO2016183366A2 · 2016 [cited by applicant]
WO WO2016197132A1 · 2016 [cited by applicant]
WO WO2016197133A1 · 2016 [cited by applicant]
WO WO2016201377A1 · 2016 [cited by applicant]
WO WO2017019891A2 · 2017 [cited by applicant]
WO WO2019207060 · 2019 [cited by applicant]
Carter (Nature Reviews Immunology vol. 6, pp. 343-357 (2006)). [cited by examiner]
Immordino ((2006). Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. International Journal of Nanomedicine, 1(3), 297-315.). [cited by examiner]
Lonez, Progress in Lipid Research 47 (2008) 340-347. [cited by examiner]
Berger (Pharmaceutics 2023, 15, 597. https://doi.org/10.3390/pharmaceutics15020597). [cited by examiner]
Lam, et al., “Pulmonary delivery of therapeutic siRNA”, Advanced Drug Delivery Reviews, ePub, vol. 64, Issue 1, pp. 1-15 (2011). [cited by applicant]
Schreier, et al., “The new frontier: gene and oligonucleotide therapy”, Pharmaceutica Acta Helvetiae, 68 Issue 3, 145-159 (1994). [cited by applicant]
Burger et al., “Sequencing complete mitochondrial and plastid genomes”, Nature Protocols, 2(3): 603-14 (2007). [cited by applicant]
Driscoll et al., “Intratracheal Instillation as an Exposure Technique for the Evaluation of Respiratory Tract Toxicity: Uses and Limitations”, Toxicological Sciences, 55: 25-35 (2000). [cited by applicant]
Kormann et al., “Expression of therapeutic proteins after delivery of chemically modified mRNA in mice”, Nature Biotechnology, 29(2): 154-9 (2011). [cited by applicant]
Rudolph et al., “Methodological optimization of polyethylenimine (PEI)-based gene delivery to the lungs of mice via aerosol application”, The Journal of Gene Medicine, 7: 59-66 (2005). [cited by applicant]
Rudolph et al., “Aerosolized Nanogram Quantities of Plasmid DNA Mediate Highly Efficient Gene Delivery to Mouse Airway Epithelium”, Molecular Therapy, 12(3): 493-501 (2005). [cited by applicant]
Su et al. “InVitro and in Vivo mRNA Delivery Using Lipid-Enveloped pH-Responsive Polymer Nanoparticles”, Molecular Pharmaceutics, 8(3): 774-787 (2011). [cited by applicant]
Phua et al. “Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format”, Journal of Controlled Release, 166:227-233 (2013). [cited by applicant]
Liu et al. “Solid lipid nanoparticles for pulmonary delivery of insulin”, Int'l Jour Pharmaceutics, 356:333-344 (2008). [cited by applicant]
Ryan et al. “Advances in PEGylation of important biotech molecules: delivery aspects” Expert Opin Drug Deliv 5(4):371-383 (2008). [cited by applicant]
Pardi et al. “Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes”, Journal of Controlled Release, 217:345-351 (2015). [cited by applicant]
Smola et al. “Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases” International Journal of Nanomedicine, 3:1-19 (2008). [cited by applicant]
Love, K. et al., “Lipid-like materials for low-dose, in vivo gene silencing”, PNAS, 107 (5): 1864-1869 (2010). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2013/044771, mailed Nov. 1, 2013 (13 pages). [cited by applicant]
Alton et al., “A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis”, Nation… [cited by applicant]